logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12630883 B1

PDFFull Text
Date of Patent:
May. 19, 2026

Filed:

May. 09, 2023

Test method of dividing blastic plasmacytoid dendritic cell neoplasm (bpdcn) into subtypes

Applicant:

Japanese Foundation for Cancer Research, Tokyo, JP;

Inventors:

Kengo Takeuchi, Tokyo, JP;

Kana Sakamoto, Tokyo, JP;

Ryohei Katayama, Tokyo, JP;

Seiji Sakata, Tokyo, JP;

Assignee:

JAPANESE FOUNDATION FOR CANCER RESEARCH, Tokyo, JP;

Attorney:

Rankin, Hill & Clark LLP

Primary Examiner:

Sarae L Bausch

Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); A61K 31/167 (2006.01); A61K 31/4045 (2006.01); A61K 31/4745 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/635 (2006.01); A61K 31/675 (2006.01); A61K 45/00 (2006.01); A61P 35/02 (2006.01); A61P 43/00 (2006.01); G01N 33/50 (2006.01); G01N 33/575 (2026.01); G01N 33/57505 (2026.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/167 (2013.01); A61K 31/4045 (2013.01); A61K 31/4745 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/635 (2013.01); A61K 31/675 (2013.01); A61K 45/00 (2013.01); A61P 35/02 (2018.01); A61P 43/00 (2018.01); G01N 33/5011 (2013.01); G01N 33/5023 (2013.01); G01N 33/5047 (2013.01); G01N 33/57505 (2026.01); G01N 33/57575 (2026.01); C12Q 2600/158 (2013.01); G01N 2333/82 (2013.01); G01N 2800/56 (2013.01);
Abstract

The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

Find Patent Forward Citations

Takeuchi, Kengo. (2026). Test method of dividing blastic plasmacytoid dendritic cell neoplasm (bpdcn) into subtypes (U.S. Patent No. 12630883). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12630883

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…